Pivmecillinam for Treatment of Uncomplicated Urinary Tract Infection: New Efficacy Analysis
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciaf280 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Thomas P Lodise und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York, USA. Hauptthemen laut MEDLINE: Urinary Tract Infections, Anti-Bacterial Agents, Amdinocillin Pivoxil. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UTILITY therapeutics.
Abstract (Originalsprache)
Background
In April 2024—over 40 years after its first approval in Europe—pivmecillinam received approval from the United States Food and Drug Administration (FDA) for the treatment of uncomplicated urinary tract infection (uUTI) in women aged ≥18 years, caused by susceptible isolates of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus. Herein, we describe the reanalysis from previously published clinical trials, conducted in accordance with current FDA efficacy criteria, which formed the basis for this regulatory approval.
Methods
Of 14 studies reviewed, 3 randomized, controlled trials offered suitable subject-level data from patients with uUTI treated with 185 mg pivmecillinam 3 times daily for 3–7 days. Efficacy endpoints for reanalysis were rates of overall (composite clinical and microbiological), clinical, and microbiological response in the microbiological intention-to-treat population (urine culture ≥105 colony-forming units/mL; ≤2 microorganism species; no baseline pathogen nonsusceptible to active comparator).
Results
Across the 3 primary studies, overall success rates with pivmecillinam at test of cure (Days 7–15) were 62.0%–71.7% (clinical success, 63.5%–82.7%; microbiological success, 74.3%–86.9%). Overall success was higher for pivmecillinam than for placebo (95% confidence interval for the difference, 41.2–62.0) or ibuprofen (31.2–56.5) and similar to cephalexin (−15.6 to 7.4). Response to pivmecillinam was demonstrated in uUTIs caused by Enterobacterales, including E. coli, P. mirabilis, and Klebsiella pneumoniae, as well as gram-positive S. saprophyticus.
Conclusions
This reanalysis of randomized, controlled trial data confirmed the efficacy of oral pivmecillinam in uUTI and was used to support its recent approval in the United States.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York, USA.
- Biostatistics, UTILITY therapeutics, London, United Kingdom.
- AD Stat Consulting, Guerneville, California, USA.
- Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.
- Department of Medicine, VA Boston and Boston University School of Medicine, Boston, Massachusetts, USA.
- College of Pharmacy and College of Medicine, University of Illinois-Chicago, Chicago, Illinois, USA.
ORCID-Profile: Thomas P Lodise, Niels Frimodt-Møller, Keith A Rodvold, Anne Santerre Henriksen, Morten O A Sommer, Florian Wagenlehner, Keith S Kaye
Förderung
- UTILITY therapeutics
Zitieren
APA
Lodise, T. P., Das, A. F., Frimodt-Møller, N., Gupta, K., Rodvold, K. A., Santerre Henriksen, A., Sommer, M. O. A., Wagenlehner, F., & Kaye, K. S. (2025). Pivmecillinam for Treatment of Uncomplicated Urinary Tract Infection: New Efficacy Analysis. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf280
Vancouver
Lodise TP, Das AF, Frimodt-Møller N, Gupta K, Rodvold KA, Santerre Henriksen A, et al. Pivmecillinam for Treatment of Uncomplicated Urinary Tract Infection: New Efficacy Analysis. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf280
BibTeX
@article{Lodise2025,
author = {Lodise, Thomas P and Das, Anita F and Frimodt-Møller, Niels and Gupta, Kalpana and Rodvold, Keith A and Santerre Henriksen, Anne and Sommer, Morten O A and Wagenlehner, Florian and Kaye, Keith S},
title = {Pivmecillinam for Treatment of Uncomplicated Urinary Tract Infection: New Efficacy Analysis},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciaf280}
}
EUVIMED